TelyRx Expands Women's Health Offerings with New Menopause Supplement

TelyRx adds SISTERLY’s menopause supplement, expanding its U.S. women’s health platform.

What the company is saying

TelyRx Holdings Inc. is announcing a partnership with SISTERLY to broaden its women's health offerings, specifically targeting women navigating perimenopause and menopause. The company highlights that it will be the first U.S. pharmacy partner to offer SISTERLY’s flagship supplement, The Elevator, which contains 23 nutrients in a daily powder sachet. Vanessa Slowey, President and CEO of TelyRx, frames the expansion as part of a holistic approach, emphasizing choice and accessibility for women. Jennifer O'Connell, SISTERLY’s Co-CEO and co-founder, underscores the shared belief in providing more options for women during menopause. The announcement stresses operational scale, citing TelyRx’s service to patients across 48 U.S. states and all territories, access to over 500 FDA-approved medications, and coverage of more than 60 health conditions. The partnership is timed to launch during World Menopause Month in October, positioning the move as both timely and relevant. The tone is confident and positive, but the company does not disclose any financial terms, sales projections, or clinical efficacy data for the supplement.

What the data suggests

The partnership is operationally realised, with TelyRx set to offer SISTERLY’s The Elevator supplement as part of its platform. TelyRx’s infrastructure spans 48 U.S. states and all territories, with access to over 500 FDA-approved medications for more than 60 health conditions, indicating significant reach. The Elevator is described as containing 23 nutrients, but no clinical trial data, sales numbers, or uptake figures are provided. Claims about the supplement’s efficacy, its 'premium' status, and its development with leading experts are not substantiated with evidence or named collaborators. The announcement is specific about operational expansion but omits any financial metrics or customer usage statistics, making it impossible to assess the partnership’s business impact. The narrative is aspirational and positions the partnership as a differentiator, but the lack of quantitative outcomes or KPIs limits the ability to evaluate its significance for investors.

Analysis

The announcement is upbeat, highlighting a new partnership and product launch timed for World Menopause Month. Most claims are realised and operational: the partnership is signed, the product is being added to the platform, and TelyRx's infrastructure and reach are described with specific numbers (48 states, 500+ medications, 60+ conditions). However, several claims about the supplement's efficacy, its 'premium' nature, and its development with 'leading' experts are not substantiated with clinical data or named collaborators. The language around 'holistic women's health offering' and 'making it easier for women' is aspirational, with no evidence of actual patient outcomes or uptake. No financial metrics, sales projections, or customer growth figures are disclosed, limiting the ability to assess business impact. The operational expansion is real, but the narrative inflates the significance of the partnership without quantifying its effect.

Risk flags

• ●The absence of disclosed financial terms, sales projections, or customer uptake figures means investors cannot assess the revenue impact or commercial significance of the partnership. This limits transparency and makes it difficult to gauge whether the expansion will drive meaningful growth.
• ●Claims about the supplement’s health benefits, premium status, and development with leading experts are not supported by clinical data, efficacy results, or named collaborators. This raises the risk that the product’s differentiation is more marketing-driven than evidence-based, which could affect long-term credibility and adoption.
• ●The announcement relies on broad, qualitative statements about improving access and offering holistic care, but provides no measurable outcomes, user feedback, or KPIs. Without data, it is unclear whether the expanded offering will translate into improved customer retention or market share.

Bottom line

TelyRx’s partnership with SISTERLY adds a branded menopause supplement to its U.S. pharmacy platform, expanding its women’s health portfolio in time for World Menopause Month. The company’s operational reach is significant, serving 48 states and all territories with over 500 medications for 60+ conditions, but the announcement provides no financial or clinical evidence to support claims of impact. The supplement’s efficacy and commercial potential remain unproven, as no sales, uptake, or outcome data are disclosed. For investors, the move signals a continued focus on product breadth and platform differentiation, but the lack of quantifiable results means the business significance is uncertain. The most important takeaway is that while the partnership is real and operational, its value to shareholders will depend entirely on future evidence of customer adoption and revenue contribution.

Announcement summary

(TSX:TELY) (OTCQX:TELYF) TelyRx Holdings Inc. announced an expansion of its women's health offering through a new partnership with SISTERLY, an Irish female-founded wellness brand specializing in science-led nutritional supplements for women. TelyRx will become the first U.S. pharmacy partner to offer SISTERLY’s flagship supplement, The Elevator, a premium daily multivitamin developed in collaboration with doctors, nutritionists, scientists, and women’s health specialists. The Elevator is formulated with 23 nutrients in a daily powder sachet, designed to support energy, immune function, hormonal regulation, and the maintenance of healthy skin, hair, and nails, specifically targeting women navigating midlife and menopause. The partnership launches in October during World Menopause Month, further broadening the range of options available to women dealing with perimenopause and menopause symptoms on the TelyRx platform. Vanessa Slowey, President and Chief Executive Officer of TelyRx, stated that the company is building a holistic women's health offering to provide more choices for women experiencing menopause. Jennifer O'Connell, Co-CEO and co-founder of SISTERLY, commented that the partnership will help bring The Elevator to more women in the U.S. through TelyRx’s expanding menopause offering. TelyRx’s platform connects customers with independent, state-licensed healthcare providers for clinical review and prescription, with fulfillment by licensed U.S. pharmacists and direct delivery. The company’s infrastructure includes a proprietary physician network, compliant prescribing workflows, licensed pharmacy operations, established medication sourcing relationships, and fulfillment infrastructure built for scale. TelyRx serves patients across 48 U.S. states and all territories, providing access to more than 500 FDA-approved medications for over 60 common health conditions. SISTERLY’s supplement, The Elevator, has won multiple awards and is tailored to female nutritional needs, supporting energy, immunity, hormonal function, and healthy skin and hair. The partnership aims to make it easier for women to access both prescription and nutritional support for menopause through a single platform.

Disagree with this article?